All press releases | Innate Pharma

Innate Pharma highlights abstracts selected for ASCO 2024 Annual Meeting

May 24, 2024
Innate Pharma reports first quarter 2024 business update and financial results

May 14, 2024
Innate Pharma reports Full Year 2023 financial results and business update

March 21, 2024
Innate Pharma reports third quarter 2023 financial results and business update

November 14, 2023
Innate Pharma announces abstracts selected for ESMO congress 2023

October 16, 2023
Innate Pharma Reports First Half 2023 Financial Results And Business Update

September 14, 2023
Innate Pharma Reports First Quarter 2023 Financial Results And Business Update

May 10, 2023
Innate Pharma highlights clinical abstracts selected for ASCO 2023 annual meeting

May 3, 2023
Innate Pharma reports Full Year 2022 Financial Results and Business Update

March 23, 2023
Innate Pharma Reports Third Quarter Financial Results

November 14, 2022

Company
Science
Products
- Pipeline overview
- ------------------
- Lacutamab
- IPH4502
- Monalizumab
- Other Clinical Stage Assets
  - IPH6501
  - IPH6101
  - IPH6401
  - IPH5201
  - IPH5301
Partnering
Investors
Media
Careers